



**Attn: Trading and Market Making/Legal and Compliance/Operations/Systems
UNIFORM PRACTICE ADVISORY (UPC #17-24) 04/05/2024 IPI Legacy
Liquidation Co (F/K/A Impel Pharmaceuticals Inc) (IMPLQ)**

Notice has been received that the above Debtors First Amended Joint Plan of Liquidation became effective on 4/05/2024. On the Effective Date, each holder of each Existing Equity Interests in any of the Debtors shall have such Interests cancelled, released, and extinguished and without any distribution or compensation. See the Debtors First Amended Joint Plan of Liquidation for more details.¹

Members are reminded of their obligations under FINRA Rule 2111 if they continue to engage in transactions in the above security after the effective date.

Pursuant to FINRA Rule 11530, members are advised that, among other things, in contracts for securities where a public announcement or publication of general circulation discloses that the securities have been deemed worthless, deliveries shall consist a) the worthless securities or; or b) a Letter of Indemnity which shall grant the purchaser any rights and privileges which might accrue to the holders of the physical securities. Such deliveries shall operate to close-out the contract and shall be settled at the existing contract price pursuant to FINRA Rule 11530.

Questions regarding this notice should be directed to: FINRA Market Operations- 1-866-776-0800.

¹ See *e.g.*, In re: Impel Pharmaceuticals INC., *et al.*, Chapter 11 Case No. 23-80016 Debtors First Amended Joint Plan of Liquidation of Impel Pharmaceuticals Inc and Impel Neuropharma Australia Pty Ltd